Research article

Replication of the genetic effects of IFN regulatory factor 5 (IRF5) on systemic lupus erythematosus in a Korean population

Hyoung Doo Shin1, Yoon-Kyong Sung2, Chan-Bum Choi2, Soo Ok Lee1, Hye Won Lee1 and Sang-Cheol Bae2

1Department of Genetic Epidemiology, SNP Genetics Inc., Rm 1407, 14th floor, Complex B, WooLim Lion’s Valley, 371-28, Gasan-Dong, Geumcheon-Gu, Seoul 153-801, Korea
2Department of Internal Medicine, Division of Rheumatology, Hospital for Rheumatic Diseases, Hanyang University, 17 Hangdang Dong, Sungdong-Gu, Seoul 133-792, Korea

Corresponding author: Sang-Cheol Bae, scbae@hanyang.ac.kr

Received: 22 Jan 2007 Revisions requested: 16 Feb 2007 Revisions received: 12 Mar 2007 Accepted: 27 Mar 2007 Published: 27 Mar 2007

Arthritis Research & Therapy 2007, 9:R32 (doi:10.1186/ar2152)

Abstract

Recently, two studies provided convincing evidence that IFN regulatory factor 5 (IRF5) gene polymorphisms are significantly associated with systemic lupus erythematosus (SLE) in several white populations. To replicate the association with SLE in an Asian population, we examined the genetic effects in our SLE cohort from a Korean population. A total of 1,565 subjects, composed of 593 cases and 972 controls, were genotyped using the TaqMan® (Applied Biosystems, Foster City, CA, USA) method. The genetic effects of polymorphisms on the risk of SLE were evaluated using χ² tests and a Mantel–Haenszel meta-analysis. Statistical analysis revealed results in the Korean population were similar to the previous reports from white populations. The rs2004640 T allele had a higher frequency in SLE cases (0.385) than controls (0.321; odds ratio (OR) = 1.32, P = 0.0003). In combined analysis, including all seven independent cohorts from the three studies so far, robust and consistent associations of the rs2004640 T allele with SLE were observed. The estimate of risk was OR = 1.44 (range, 1.34–1.55), with an overall P = 1.85 × 10⁻²³ for the rs2004640 T allele. The haplotype (rs2004640T–rs2280714T) involved in both the alternative splice donor site and the elevated expression of IRF5 also had a highly significant association with SLE (pooled, P = 2.11 × 10⁻¹⁶). Our results indicate that the genetic effect on the risk of SLE mediated by IRF5 variants can be generally accepted in both white and Asian populations.

Introduction

Recently, two studies provided convincing evidence that IFN regulatory factor 5 (IRF5 [MIM 607218]) gene polymorphisms are significantly associated with systemic lupus erythematosus (SLE [MIM 152700]). The studies included – seven independent SLE cohorts from white populations (Sweden-1, Finland, Iceland, USA, Spain, Sweden-2 and Argentina) and involved both family-based and case-control cohorts [1,2]. In both studies, the dbSNP rs2004640 (T > G) of IRF5 showed strong associations with the risk of SLE, for example higher frequencies in SLE cases than controls (combined analysis, 61% in SLE cases versus 51% in controls; P = 4.2 × 10⁻²¹). Graham and colleagues, through further experiments in the later study, also identified a common (frequency, 50.0% in white populations) IRF5 haplotype that has both a splice donor site, which allows expression of multiple IRF5 isoforms containing exon 1B, and a separate genetic effect associated with elevated levels of expression of IRF5 [1]. To replicate the association with SLE in an Asian population, we examined the genetic effects in our SLE cohort from a Korean population.

Materials and methods

A total of 593 Korean SLE patients (mean age, 32.36 (6.99–70.7); male = 35 and female = 558) who fulfilled the 1997 American College of Rheumatology (ACR) criteria for SLE [3] were consecutively enrolled between September 1998 and February 2005 at the Hospital for Rheumatic Diseases, Hanyang University, Seoul, Korea. The following clinical and

ACR = American College of Rheumatology; dbSNP = database of SNP; IFN = interferon; IRF5 = IFN regulatory factor 5; OR = odds ratio; SAS = statistical analysis system; SLE = systemic lupus erythematosus; SLICC = Systemic Lupus International Collaborating Clinics; SNP = single nucleotide polymorphism.
laboratory data were obtained: sex, age, ages at onset of first symptom and clinical diagnosis, ACR diagnosis, and Systemic Lupus International Collaborating Clinics (SLICC)/ACR damage index [4]. As a control group, we included 971 healthy, ethnic-matched subjects (mean age, 37.2 (16.6–78.6); male = 139 and female = 832).

Four SNPs (rs729302 (A > C), rs2004640 (G > T), rs752637 (T > C) and rs2280714 (T > C)) were genotyped, using the TaqMan® (Applied Biosystems, Foster City, CA, USA) method [5], in our SLE cases and controls from the Korean population. Information regarding the primers is available on our website [6].

χ² analyses were used to evaluate the significance of differences in genotype and allele frequencies in the case-control samples using Statistical Analysis System (SAS). The allele frequencies for cases and controls were used to calculate the odds ratio (OR) and the 95% confidence interval using SAS. For the case-control haplotype analysis, Haplovieview v3.2 (Broad Institute of Harvard and MIT Cambridge, MA, USA) was used to generate haplotype frequencies and calculate the significance of associations. The Breslow–Day statistic was used to test for homogeneity among studies. A Mantel–Haenszel meta-analysis was performed on the ORs, and these data were subsequently combined in a separate analysis with the published results of the association of rs2004640 (G > T) with SLE from previous studies [1,2]. Further conditional analyses and global haplotype tests were performed using WHAP software [7] developed by Shaun Purcell (Massachusetts General Hospital, Boston, MA, USA) and Pak Sham (Hong Kong University, Hong Kong). This analysis was used to disentangle the correlation structure in the gene, to rule out the possibility that multiple observed effects are owing to linkage disequilibrium from a single true effect.

Results and discussion
Genotype distributions of all loci were in Hardy–Weinberg equilibrium (P > 0.05). The frequency of the rs2004640 T allele, which has a central role in IRF5 polymorphisms, was significantly lower in the Korean population (frequency, 0.345) than white populations (frequency, 0.570; Table S2 in Additional file 1).

Statistical analysis revealed the results in the Korean population were similar to the previous reports from white populations [1,2]. The rs2004640 T allele was significantly associated with an increased risk of SLE (Table 1), for example it had a higher frequency in SLE cases (0.385) than controls (0.321; OR = 1.32, P = 0.0003). The two nearby SNPs (rs729302 and rs752637) that were strongly linked to rs2004640 (LD| = 0.83 and 0.98, respectively; Figure S1 in Additional file 1) and the haplotype (rs2004640T–rs2280714T) that was associated with both the alternative splice donor site and elevated levels of expression of IRF5 [1] were also significantly associated with SLE (Table 1 and Table S1 in Additional file 1).

The observation that the presence of risk haplotypes within datasets can create spurious protective effects for other haplotypes lead us to perform the same global test conditioning for the predisposing haplotype (T–T). Conditioning for the predisposing haplotype (T–T) revealed that no significant haplo-
typic association remained in the dataset (χ² (2 degrees of freedom) = 5.456, P = 0.07). These results might suggest that the risk haplotype (T–T) could explain the total association, for example the protective effect of the haplotype (G–T) was not real and could be just a shadow effect of the risk haplotype (T–T).

In combined analysis, including all eight independent cohorts (Finland, Iceland, USA, Spain, Sweden-1, Sweden-2, Argentina and Korea) from the three studies so far, robust and consistent associations of the rs2004640 T allele with SLE were observed (Table 2). The Breslow–Day test for heterogeneity was not significant for allele distributions (P = 0.7115, data not shown), suggesting the homogeneity of studies. The estimate of risk was OR = 1.44 (1.34–1.55), with an overall P = 1.85 x 10⁻²³ for the rs2004640 T allele (Table 2). The haplo-
type (rs2004640T–rs2280714T) involved in both the alternative splice donor site and the elevated levels of expression of IRF5 [1] also had a highly significant association with SLE (pooled, P = 2.11 x 10⁻¹⁶; Table S1 in Additional file 1). The strengths of the associations of both the rs2004640 T allele and the haplotype were high enough to surpass the correction for multiple testing, even with all of the variants in the human genome.

Genetic association studies provide a potentially powerful tool for identifying genetic variations that influence susceptibility to common diseases. However, there are numerous cases of associations that cannot be replicated afterwards, which have led to skepticism about genetic epidemiology studies of complex diseases [8–10]. To discourage false-positive association hypotheses, several recommendations have been suggested: large sample sizes, small P values, a gene/allele with biologically/physiologically meaningful sense, an association observed in both family- and population-based studies, repli-
cations in independent studies, and a high OR and/or attribut-
able risk [8]. Among these criteria, validation of a genetic association by replication might be the most important step to exclude false-positive associations. In statistical terms, inde-
pendent replication decreases the chances of reporting an association if no association actually exists (type I error). In the case of association of the IRF5 variant with SLE, which has satisfied most of the above criteria and been replicated among numerous white populations, additional replications among separate sets of patients with different ethnic backgrounds, such as African and/or Asian populations, would strengthen the confidence in any association study and allow significant
gains in narrowing the disease associated interval owing to different patterns of linkage disequilibrium. In this study of a Korean SLE cohort, we present associations of IRF5 variants with SLE similar to those suggested by previous studies.

Transcription factors of the IRF family have essential roles in the regulation of genes induced by viral infection and immunostimulation, in addition to regulation of cell growth. IRF5 was originally identified as a regulator of type I IFN gene expression [11]. IRF5 is regulated by type I IFN, indicating an important regulatory pathway for the controlled induction of multiple immunomodulatory genes. The constitutive expression of IRF5 is limited to lymphoid organs, dendritic cells and peripheral blood lymphocytes; however, it is absent in numerous leukaemia and lymphoma cell lines [11], which might indicate a propensity for IRF5 gene deletion or possibly silencing by methylation in these malignancies [11]. IRF5 is phosphorylated in cells on viral infection and translocates to the nucleus, which results in activation of a spectrum of IFN genes [11]. Thus, polymorphism within the IRF5 gene might affect several cellular functions of importance for the development of an autoimmune disease, such as SLE. The rs2004640 T allele creates a 5′ donor splice site in an alternate exon 1 of IRF5 and might thus have a functional role by altering the splicing of exon 1 of the IRF5 [2].

**Conclusion**

Association analysis of IRF5 polymorphisms revealed that the results in the Korean population were similar to those in the previous reports from white populations, for example the

### Table 1

| Loci                  | Associated allele | Cases (n = 593) | Controls (n = 972) | OR (95% CI)   | χ²    | P<sup>a</sup> |
|-----------------------|-------------------|----------------|-------------------|---------------|-------|---------------|
| rs729302 (A > C)      | A                 | 0.729          | 0.680             | 1.27 (1.08–1.49) | 8.44  | 0.0037       |
| rs2004640 (G > T)     | T                 | 0.385          | 0.321             | 1.32 (1.14–1.54) | 13.22 | 0.0003       |
| rs752637 (T > C)      | C                 | 0.455          | 0.398             | 1.27 (1.09–1.47) | 9.73  | 0.0018       |
| rs2280714 (T > C)     | T                 | 0.395          | 0.402             | 0.97 (0.84–1.13) | 0.15  | 0.6971       |
| Haplotype<sup>b</sup> | AGTC              | 0.355          | 0.368             | 0.95 (0.82–1.11) | 0.49  | 0.4840       |
|                       | ATCT              | 0.352          | 0.295             | 1.28 (0.10–1.50) | 10.85 | 0.001        |
|                       | CGTT              | 0.158          | 0.205             | 0.74 (0.61–0.89) | 10.21 | 0.0014       |
|                       | CGCT              | 0.066          | 0.071             | 0.96 (0.72–1.28) | 0.34  | 0.5600       |
|                       | CGTC              | 0.034          | 0.024             | 0.97 (0.63–1.50) | 0.78  | 0.3784       |
|                       | CTCT              | 0.016          | 0.017             | 1.23 (0.72–2.09) | 0.07  | 0.7919       |
| Haplotype<sup>c</sup> | T–T               | 0.380          | 0.311             | 1.36 (1.16–1.58) | 15.2  | 9.64 × 10⁻⁵  |
|                       | G–T               | 0.225          | 0.283             | 0.74 (0.62–0.87) | 12.5  | 0.0004       |
|                       | G–C               | 0.387          | 0.398             | 0.95 (0.82–1.11) | 0.4   | 0.5330       |
|                       | T–T               | 0.008          | 0.008             | 0.96 (0.42–2.21) | 0.0   | 0.9323       |

*Case-control analysis. χ² analyses were used to evaluate the significance of differences in genotype and allele frequencies in the case-control samples. The allele frequencies for cases and controls were used to calculate the OR and the 95% CI. For the case-control haplotype analysis, Haploview v3.2 (Broad Institute of Harvard and MIT Cambridge, MA, USA) was used to generate haplotype frequencies and calculate the significance of associations. CI, confidence interval; IRF5, IFN regulatory factor 5; OR, odds ratio; SLE, systemic lupus erythematosus.*

<sup>a</sup>P value, uncorrected for multiple tests.

<sup>b</sup>Haplotype consisting of markers rs729302 (A > C), rs2004640 (G > T), rs752637 (T > C) and rs2280714 (T > C).

<sup>c</sup>Haplotype consisting of markers rs2004640 (G > T) and rs2280714 (T > C).
rs2004640 T allele of IRF5 revealed a susceptible effect on the risk of SLE. These results indicate that the genetic effect on the risk of SLE mediated by IRF5 variants could be generally accepted in both white and Asian populations.

Competing interests
We have no competing interests (political, personal, religious, ideological, academic, intellectual, commercial or any other) to declare in relation to this manuscript.

Authors’ contributions
HD Shin and SC Bae have made substantial contributions to study design, acquisition of data, drafting the manuscript, and analysis and interpretation of data. YK Sung and CB Choi have been involved in drafting the manuscript or critically revising it. HW Lee carried out the molecular genetic studies, including genotyping. SO Lee performed the statistical analysis. All authors read and approved the final manuscript.

Table 2
Case-control association analysis of the IRF5 rs2004640 (G > T) T allele with SLE

|        | n    | No. of T alleles | Frequency of T alleles | No. of G alleles | Frequency of G alleles | OR (95% CI) | P< | Pooled OR | Pooled P |
|--------|------|------------------|------------------------|------------------|------------------------|------------|----|-----------|----------|
| Korea  | Cases| 589              | 454                    | 0.385            | 724                    | 0.615      | 1.32 (1.14–1.54) | 0.0003   |
|        | Controls| 950          | 610                    | 0.321            | 1290                   | 0.679      | 1.52 (1.20–1.93) | 0.00035  |
| Argentina<sup>c</sup> | Cases| 284              | 309                    | 0.54             | 259                    | 0.46       | 1.42 (1.18–1.71) | 0.00016  |
|        | Controls| 279           | 245                    | 0.44             | 313                    | 0.56       | 1.52 (1.20–1.93) | 0.00035  |
| Spain<sup>c</sup> | Cases| 444              | 559                    | 0.63             | 329                    | 0.37       | 1.47 (1.29–1.67) | 3.6 × 10<sup>-9</sup> |
|        | Controls| 541           | 589                    | 0.54             | 493                    | 0.46       | 1.42 (1.18–1.71) | 0.00016  |
| Sweden-1<sup>c</sup> | Cases| 208              | 260                    | 0.63             | 156                    | 0.38       | 1.31 (1.01–1.71) | 0.04268  |
|        | Controls| 254           | 284                    | 0.56             | 224                    | 0.44       | 1.31 (1.01–1.71) | 0.04268  |
| USA<sup>c</sup> | Cases| 725              | 879                    | 0.61             | 571                    | 0.39       | 1.47 (1.29–1.67) | 3.6 × 10<sup>-9</sup> |
|        | Controls| 1,434          | 1,467                  | 0.51             | 1,401                  | 0.49       | 1.47 (1.29–1.67) | 3.6 × 10<sup>-9</sup> |
| Sweden-2<sup>d</sup> | Cases| 480              | 595                    | 0.62             | 365                    | 0.38       | 1.51 (1.21–1.87) | 0.00002  |
|        | Controls| 256           | 266                    | 0.52             | 246                    | 0.48       | 1.51 (1.21–1.87) | 0.00002  |
| Finland<sup>d</sup> | Cases| 109              | 137                    | 0.63             | 81                     | 0.37       | 1.84 (1.27–2.66) | 0.00133  |
|        | Controls| 121           | 116                    | 0.48             | 126                    | 0.52       | 1.84 (1.27–2.66) | 0.00133  |
| Combined analysis | Cases| 2,839            | 3,193                  | 0.56             | 2,485                   | 0.44       | 1.44 (1.34–1.55) | 1.85 × 10<sup>-23</sup> |
|        | Controls| 3,835          | 3,577                  | 0.47             | 4,093                   | 0.53       | 1.44 (1.34–1.55) | 1.85 × 10<sup>-23</sup> |

Meta-analysis. Mantel–Haenszel meta-analysis of the ORs; these data were subsequently combined in a separate analysis with the published results of the association of rs2004640 (G > T) with SLE from previous studies [1,2]. The Breslow–Day test for heterogeneity was not significant for allele distributions (P = 0.7115, data not shown), suggesting the homogeneity of studies. 'Number of alleles' refers to number of alleles of rs2004640 (G > T). CI, confidence interval; IRF5, IFN regulatory factor 5; OR, odds ratio; SLE, systemic lupus erythematosus. <sup>a</sup>χ<sup>2</sup> tests were used to evaluate the significance of differences in allele frequencies in the case-control samples. <sup>b</sup>Mantel–Haenszel test [12] of pooled ORs and 95% CIs. <sup>c</sup>Data from Graham and co-workers [1]. <sup>d</sup>Data from Sigurdsson and co-workers [2].
Additional files

The following Additional files are available online:

**Additional file 1**
A DOC file containing Figure S1, which depicts LDs among IRF5 polymorphisms in a Korean population (cases and controls).
See http://www.biomedcentral.com/content/supplementary/ar2152-S1.doc

**Additional file 2**
A DOC file containing Table S1, which shows IRF5 haplotype frequency in SLE cases and controls.
See http://www.biomedcentral.com/content/supplementary/ar2152-S2.doc

**Additional file 3**
A DOC file containing Table S2, which shows frequencies of IRF5 polymorphisms and deviation from the Hardy–Weinberg equilibrium in a Korean population.
See http://www.biomedcentral.com/content/supplementary/ar2152-S3.doc

Acknowledgements

This work was supported by a grant from the Korea Health 21 R&D Project, Ministry of Health and Welfare, Korea (01-PJ3-PG6-01GN11-0002). This work was also partly supported by grant number M1-0302-00-0073 (programme of the National Research Laboratory, Ministry of Commerce, Industry and Energy, Korea).

References

1. Graham RR, Kozyrev SV, Baechler EC, Reddy MV, Plenge RM, Bauer JW, Ortmann WA, Koeuth T, Gonzalez Escriberno MF, Pons-Estel B, et al.: A common haplotype of interferon regulatory factor 5 (IRF5) regulates splicing and expression and is associated with increased risk of systemic lupus erythematosus. *Nat Genet* 2006, 38:550-555.
2. Sigurdsson S, Nordmark G, Goring HH, Lindroos K, Wiman AC, Sturfelt G, Jonsen A, Rantapaa-Dahlqvist S, Moller B, Kere J, et al.: Polymorphisms in the tyrosine kinase 2 and interferon regulatory factor 5 genes are associated with systemic lupus erythematosus. *Am J Hum Genet* 2005, 76:528-537.
3. Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997, 40:1725.
4. Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, et al.: The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. *Arthritis Rheum* 1996, 39:363-369.
5. Livak KJ: Allelic discrimination using fluorogenic probes and the S' nuclease assay. *Genet Anal* 1999, 14:143-149.
6. SNP Genetics – additional information [http://www.snp-genetics.com/user/additional_list.asp](http://www.snp-genetics.com/user/additional_list.asp)
7. Whap [http://pngu.mgh.harvard.edu/~purcell/whap/](http://pngu.mgh.harvard.edu/~purcell/whap/)
8. Editorial: Freely associating. *Nat Genet* 1999, 22:1-2.
9. Cardon LR, Bell Jr.: Association study designs for complex diseases. *Nat Rev Genet* 2001, 2:91-99.
10. Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN: Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. *Nat Genet* 2003, 33:177-182.
11. Mancl ME, Hu G, Sangster-Guity N, Olahalsky SL, Hoops K, Fitzgerald-Bocarsly P, Pitha PM, Pinder K, Barnes BJ: Two discrete promoters regulate the alternatively spliced human interferon regulatory factor-5 isoforms. Multiple isoforms with distinct cell type-specific expression, localization, regulation, and function. *J Biol Chem* 2005, 280:21078-21090.
12. Woolson RF, Bean JA: Mantel–Haenszel statistics and direct standardization. *Stat Med* 1982, 1:37-39.